Friday 6 November 2026
Export NTRA’s income statement to Excel — free account
Natera, Inc.
NTRA Healthcare Diagnostics & Research
Natera, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.3 billion, up 35.9% from fiscal 2024.
- Revenue
- +34.1%
- EPS
- +34.4%
- Free cash flow
- −85.8%
- Total debt
- −0.06%
Quarter to September 2026, against a year earlier
311.66
52.10
−14.32%
Follow NTRA
Alert me
| Sep '26 From the 10-Q filed 5 Nov | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
Piotroski F-Score |
— | 6 | 6 | 6 |
+8 more TTM periods Free account |
| (10.55%) | (12.54%) | (15.02%) | (14.32%) | ||
| (7.21%) | (8.71%) | (10.41%) | (10.26%) | ||
ROIC |
(8.35%) | (22.34%) | (26.44%) | (27.03%) | |
Return on Tangible Assets |
(11.25%) | (13.51%) | (16.60%) | (16.05%) | |
Average Days of Receivables |
59.14 | 56.89 | 60.95 | 46.93 | |
Free Cash Flow per Share |
0.36 | 0.59 | 0.74 | 0.80 | |
Free Cash Flow |
52.47 | 84.20 | 104.51 | 109.11 | |
Capital Expenditures |
(160.32) | (144.04) | (106.51) | (106.19) | |
| Other line items | |||||
Cash ROIC |
2.69% | 2.81% | 3.55% | 3.80% | |
Accounts Receivable Turnover |
7.68 | 7.40 | 6.80 | 7.55 | |
Accounts Payable Turnover |
0.00 | 16.80 | 17.19 | 23.88 | |
Inventory Turnover |
0.00 | 13.98 | 14.43 | 14.36 | |
Average Days of Payables |
0.00 | 29.14 | 26.07 | 14.89 | |
Days of Inventory on Hand |
0.00 | 31.16 | 29.55 | 30.73 | |
Tax Rate |
(0.27) | (0.24) | (0.21) | (0.22) | |
Research and Development Expense of Revenue |
29.44% | 29.09% | 28.22% | 27.06% | |
Selling, General and Administrative Expense of Revenue |
44.01% | 46.36% | 49.52% | 51.05% | |
Share Based Compensation of Revenue |
13.64% | 14.09% | 14.86% | 15.37% | |
Interest Coverage |
— | (75.89) | (81.96) | (76.16) | |
Operating CF/Net income |
(1.29) | (1.19) | (0.93) | (1.03) | |
Depreciation/Fixed assets |
0.00 | 0.21 | 0.20 | 0.18 | |
Capex/Depreciation |
0.00 | (2.19) | (1.95) | (2.44) | |
Revenue per Share |
20.19 | 18.89 | 17.67 | 16.87 | |
Operating CF per Share |
1.48 | 1.59 | 1.49 | 1.57 | |
Capex per Share |
(1.11) | (1.01) | (0.75) | (0.78) | |
Capex to Sales |
0.06 | 0.05 | 0.04 | 0.05 |
Columns are period end dates · fundamentals updated 5 Nov 2026